When was Telix Pharma founded?

Telix Pharma was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Where is Telix Pharma located?

Telix Pharma is headquartered in Melbourne, Australia.

How many employees does Telix Pharma have?

As of Jul 31, 2026, the latest employee count at Telix Pharma is 1201.

Is Telix Pharma a funded company?

Telix Pharma is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Nov 02, 2020.

When was the latest funding round of Telix Pharma?

Telix Pharma's latest funding was a $***** Post IPO round on Nov 02, 2020, with participation from 1 investor.

Where does Telix Pharma rank among its competitors?

Telix Pharma ranks 411th amongst 2607 active competitors, of which 896 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Telix Pharma?

Telix Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Telix Pharma - 2026 Company Profile, Funding & Competitors

Company Details

Developer of theranostic radiopharmaceuticals for imaging and treating cancer. It offers TX250, a Girentuximab antibody with an imaging payload (124-I or 177-Lu), targeting carbonic anhydrase IX, indicated for CCRC, and treatment with 177Lu and NSCLC.

Website: telixpharma.com
Social

Key Metrics

Founded Year

2015

Location

Melbourne, Australia

Stage

Public

Latest Funding Round

Post IPO, Nov 02, 2020, $*****

Investors

China Grand Pharmaceutical and Healthcare

Ranked

411^th among 2607 active competitors

Employee Count

1,201 as on Jul 31, 2026

Investment & Acquisitions

RLS & 9 more

Similar Companies

Molecular Partners & 230 more

Exit Details

Public

View Telix Pharma's full profile

Telix Pharma got listed on Nov 15, 2017.

Click here to take a look at Telix Pharma's IPO in detail

Telix Pharma has raised funding over 1 round. Its latest funding round was a Post IPO round on Nov 02, 2020 for $*****. 1 investor participated in its latest round. Telix Pharma has 1 institutional investor.

Here is the list of recent funding rounds of Telix Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 02, 2020	2615582	Post IPO	3851700	7276433	6286720	8487016

Access funding benchmarks and valuations. Sign up today!

View details of Telix Pharma's funding rounds and investors

Telix Pharma's employee count trend

Telix Pharma has 1,201 employees as of Jul 26. Here is Telix Pharma's employee count trend over the years:

Uncover Telix Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Telix Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Telix Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
411th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Telix Pharma's competitors? Click here to see the top ones

Telix Pharma has made 1 investments in companies including Mauna Kea Tech. Telix Pharma has also acquired 9 companies including RLS and ARTMS.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Sep 23, 2024	Acquisition	RLS	2018	Miami (United States)
Mar 05, 2024	Acquisition	ARTMS	2013	Vancouver (Canada)
Feb 27, 2024	Acquisition	IsoTherapeutics Group	2005	Angleton (United States)